Literature DB >> 2316012

Characterization and significance of donor-reactive B cell antibodies in current sera of kidney transplant patients.

S S Karuppan1, A Lindholm, E Möller.   

Abstract

The specificity and class of antibodies resulting in a positive B cell crossmatch were studied in 47 kidney-transplanted patients. The study was performed to determine instances where a positive B cell crossmatch would not be deleterious to the survival of the graft. In order to determine the specificity and class of the antibodies, we used monoclonal antibodies to HLA-A,B,C and DR antigens to block cytotoxicity of sera, and the reagent DTT to characterize the immunoglobulin class. We found that graft survival in patients with DR antibodies was significantly better than in patients with class I antibodies (P less than 0.02). No difference in graft survival in patients with IgM antibodies versus patients with IgG antibodies was observed. The presence of weak HLA class I antibodies in patient's sera only detected as reactivity on B lymphoid cells should be considered a contraindication to transplantation. Thus our study shows that a fraction of patients who have cytotoxic B cell reactive antibodies at the time of transplantation can be successfully transplanted, provided the specificity of each serum is defined prior to transplantation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2316012     DOI: 10.1097/00007890-199003000-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Preformed lymphocytotoxic antibodies: the effects of class, titer and specificity on liver vs. heart allografts.

Authors:  T Furuya; N Murase; K Nakamura; J Woo; S Todo; A J Demetris; T E Starzl
Journal:  Hepatology       Date:  1992-12       Impact factor: 17.425

2.  Renal transplantation performed across a positive crossmatch: a single centre experience.

Authors:  S F Leavey; J J Walshe; D O'Neill; N Atkins; J Donohoe; D Hickey; M Carmody
Journal:  Ir J Med Sci       Date:  1997 Oct-Dec       Impact factor: 1.568

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.